Drug targeting via retrometabolic approaches

Pharmacology and Therapeutics

Volumn 76, Issue 1-3, 1997, Pages 1-27

  Bodor, Nicholas ^a   Buchwald, Peter ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Brain targeting; Eye targeting; Molecular packaging; Peptide delivery; Soft blockers; Soft anticholinergics

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CETYLPYRIDINIUM SALT; CHLORAMBUCIL; CHLORPHENOTANE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ESTRADIOL; HOMATROPINE METHYL BROMIDE; HYDROCORTISONE; LOTEPREDNOL ETABONATE; METHYLSCOPOLAMINE; METOPROLOL; NALOXONE; OXIME; PROSTAGLANDIN E1; PROTIRELIN DERIVATIVE;

BLOOD BRAIN BARRIER; COMPUTER PROGRAM; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; EXPERT SYSTEM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031278026     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00098-3     Document Type: Review

References (113)

1. Abou-Donia, M. B. and Menzel, D. B. (1968) The metabolism in vivo of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT), 1,1-dichloro-2,2-bis(p-chlorophenyl)ethane (DDD) and 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) in the chick by embryonic injection and dietary ingestion. Biochem. Pharmacol. 17: 2143-2161.
2. 2. J. Pharm. Sci. 84: 523-529.
3. Bodor, N. (1977) U.S. Patent 4061722, December 6.
4. Bodor, N. (1982a) Soft drugs: strategies for design of safer drugs. In: Strategy in Drug Research, Proceedings of the 2nd IUPAC-IUPHAR Symposium on Research, Noordwijkerhout, The Netherlands, pp. 137-164, Ruisman, J. A. K. (ed.) Elsevier, Amsterdam.
5. Bodor, N. (1982b) Designing safer drugs based on the soft drug approach. Trends Pharmacol. Sci. 3: 53-56.
6. Bodor, N. (1983) Soft drugs: strategies for design of safer drugs. In: Metabolisme et Conception Medicaments: Quo Vadis? Proceedings of Symposium at Montpellier, France, November 26-27, 1981, pp. 217-251, Briot, M., Cautreels, W. and Roncucci, R. (eds.) CLIN MIDY, Montpellier.
7. Bodor, N. (1984a) The soft drug approach. Chemtech 14(1): 28-38.
8. Bodor, N. (1984b) Soft drugs: principles and methods for the design of safe drugs. Med. Res. Rev. 3: 449-469.
9. Bodor, N. (1984c) Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems. In: Advances in Drug Research, Vol. 13, pp. 255-331, Testa, B. (ed.) Academic Press, London.
10. Bodor, N. (1985) Novel approaches to the design of safer drugs by site-specific chemical delivery systems. In: Advances in Drug Delivery Systems, pp. 111-127, Tipnis, H. P. (ed.) MSR Foundation, Bombay.
11. Bodor, N. (1987) Redox drug delivery systems for targeting drugs to the brain. Ann. NY Acad. Sci. 507: 289-306.
12. Bodor, N. (1988) The application of soft drug approaches to the design of safer corticosteroids. In: Topical Corricosteroid Therapy: A Novel Approach to Safer Drugs, pp. 13-25, Christophers, E., Kligman, A. M., Schöpf, E. and Stougton, R. B. (eds.) Raven Press Ltd., New York.
13. Bodor, N. (1989) Designing safer ophthalmic drugs. In: Trends in Medicinal Chemistry '88, Proceeding of the Xth International Symposium on Medicinal Chemistry, pp. 145-164, van der Goot, H., Domany, G., Pallos, L. and Timmerman, H. (eds.) Elsevier, Amsterdam.
14. Bodor, N. (1991) Soft drugs. In: Encyclopedia of Human Biology, Vol. 7, pp. 101-117, Dulbecco, R. (ed.) Academic Press, San Diego.
15. Bodor, N. (1992) New methods of drug targeting. In: Trends in Medicinal Chemistry '90, pp 15-44, Sarel, S., Mechoulam, R. and Agranar, I. (eds.) Blackwell Scientific Publications, Oxford.
16. Bodor, N. (1993) Design of novel soft corticosteroids. In: Topical Glucocorticoids with Increased Benefit-Risk Ratio, Vol. 21, Current Problems in Dermatology, pp. 11-19, Korting, H. (ed.) Karger AG, Basel.
17. Bodor, N. (1994) Drug targeting and retrometabolic drug design approaches. Adv. Drug Delivery Rev. 14: 157-166.
18. Bodor, N. (1995a) Design of biologically safer chemicals. Chemtech 25(10): 22-32.
19. Bodor, N. (1995b) Retrometabolic drug design concepts in ophthalmic target-specific drug delivery. Adv. Drug Delivery Rev. 16: 21-18.
20. Bodor, N. (1995c) Retrometabolic approaches to drug targeting. In: NIDA Research Monograph Series, Vol. 154, Membranes and Barriers: Targeted Drug Delivery, pp. 1-27, Rapaka, R. (ed.) NIDA, Rockville.
21. Bodor, N. (1995d) Targeting drugs to the brain by sequential metabolism. In: NIDA Research Monograph Series, Vol. 147, Discovery of Novel Opioid Medications, pp. 1-32, Rapaka, R. and Sorer, H. (eds.) NIDA, Rockville.
22. Bodor, N. and Brewster, M. E. (1983) Problems of delivery of drugs to the brain. Pharmacol. Ther. 19: 337-386.
23. Bodor, N. and Brewster, M. E. (1991) Chemical delivery systems. In: Handbook of Experimental Pharmacology, Vol. 100, Targeted Drug Delivery, pp. 231-284, Juliano, R. L. (ed.) Springer-Verlag, Berlin.
24. Bodor, N. and Buchwald, P. (1997) Molecular size based approach to estimate partition properties for organic solutes. J. Phys. Chem. B 101: 3404-3412.
25. Bodor, N. and Farag, H. H. (1983) Improved delivery through biological membranes. 11. A redox chemical drug-delivery system and its use for brain specific delivery of phenylethylamme. J. Med. Chem. 26: 313-318.
26. Bodor, N. and Freiberg, E. (1981) U.S. Patent 4262765, April 28.
27. Bodor, N. and Huang, M.-J. (1992a) An extended version of a novel method for the estimation of partition coefficients. J. Pharm. Sci. 81: 272-281.
28. Bodor, N. and Huang, M.-J. (1992b) A new method for the estimation of the aqueous solubility of organic compounds. J. Pharm. Sci. 81: 954-960.
29. Bodor, N. and Huang, M.-J. (1994) Computer-aided design of new drugs based on retrometabolic concepts. In: Computer-Aided Molecular Design. Applications in Agrochemicals, Materials, and Pharmaceuticals, ACS Symposium Series 589, pp. 98-113, Reynolds, C. H., Holloway, M. K. and Cox, H. K. (eds.) American Chemical Society, Washington, DC.
30. Bodor, N. and Huang, M.-J. (1996) Computational approaches to the design of safer drugs and their molecular properties. In: Computational Chemistry: Reviews of Current Trends, Vol. 1, pp. 219-266, Leszczynski, J. (ed.) World Scientific, Singapore.
31. Bodor, N. and Kaminski, J. J. (1980) Soft drugs. 2. Soft alkylating compounds as potential antitumor agents. J. Med. Chem. 23: 566-569.
32. Bodor, N. and Kaminski, J. J. (1987) Prodrugs and site-specific chemical delivery systems. Annu. Rep. Med. Chem. 22: 303-313.
33. Bodor, N. and Oshiro, Y. (1983) Japan Patent 21201, February 10.
34. Bodor, N. and Prokai, L. (1990) Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation. Pharm. Res. 7: 723-725.
35. Bodor, N. and Prokai, L. (1995) Molecular packaging: peptide delivery to the central nervous system by sequential metabolism. In: Peptide-Based Drug Design: Controlling Transport and Metabolism, pp. 317-337, Taylor, M. and Amidon, C. (eds.) American Chemical Society, Washington, DC.
36. Bodor, N. and Sloan, K. B. (1982) Soft drugs. V. Thiazolidine-type derivatives of progesterone and testosterone. J. Pharm. Sci. 71: 514-520.
37. Bodor, N. and Visor, G. (1984) Formation of adrenaline in the irisciliary body from adrenalone diesters. Exp. Eye Res. 38: 621-626.
38. Bodor, N., Kaminski, J. J. and Selk, S. (1980a) Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J. Med. Chem. 23: 469-474.
39. Bodor, N., Woods, R., Raper, C., Kearney, P. and Kamitiski, J. (1980b) Soft drugs. 3. A new class of anticholinergic agents. J. Med. Chem. 23: 474-480.
40. Bodor, N., Farag, H. H. and Brewster, M. E. (1981) Site-specific, sustained release of drugs to the brain. Science 214: 1370-1372.
41. Bodor, N., Sloan, K. B., Little, R. J., Selk, S. H. and Caldwell, L. (1982) Soft drugs. 4. 3-Spirothiazolidines of hydrocortisone and its derivatives. Int. J. Pharm. 10: 307-321.
42. Bodor, N., Oshiro, Y., Loftsson, T., Katovich, M. and Caldwell, W. (1984) Soft drugs. VI: the application of the inactive metabolite approach for design of soft β-blockers. Pharm. Res. 3: 120-125.
43. Bodor, N., McComack, J. and Brewster, M. E. (1987) Improved delivery through biological membranes. XXII. Synthesis and distribution of brain-selective estrogen delivery systems. Int. J. Pharm. 35: 47-59.
44. Bodor, N., El-Koussi, A., Kano, M. and Khalifa, M. (1988a) Soft drugs. 7. β-Blockers for systemic and ophthalmic use. J. Med. Chem. 31: 1651-1656.
45. Bodor, N., El-Koussi, A., Kano, M. and Nakamuro, T. (1988b) Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for β-adrenergic blocking agents. J. Med. Chem. 31: 100-106.
46. Bodor, N., Gabanyi, Z. and Wong, C.-K. (1989) A new method for the estimation of partition coefficient. J. Am. Chem. Soc. 111: 3783-3786.
47. Bodor, N., El-Koussi, A. and Hammer, R. (1990) Soft drugs. 9. The ultra-short duration of the muscarinolytic activity of a new short-acting "soft" mydriatic agent. J. Biopharm. Sci 1: 215-223.
48. Bodor, N., Harget, A. and Huang, M.-J. (1991) Neural network studies. 1. Estimation of the aqueous solubility of organic compounds. J. Am. Chem. Soc. 113: 9480-9483.
49. Bodor, N., Bodor, N. and Wu, W.-M. (1992a) A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr. Eye Res. 11: 525-530.
50. Budor, N., Prokai, L., Wu, W.-M., Farag, H. H., Jonnalagadda, S., Kawamura, M. and Simpkins, J. (1992b) A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 257: 1698-1700.
51. Bodor, N., Buchwald, P. and Huang, M.-J. (1997a) Computer assisted design of new drugs based on retrometabolic concepts. SAR QSAR Environ. Res., 13: 389-403.
52. Bodor, N., Farag, H. H., Somogyi, G., Wu, W.-M., Barros, M. D. C. and Prokai, L. (1997b) Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs. J Ocul. Pharmacol., in press.
53. Brewster, M. E. and Bodor, N. (1994) Improved brain delivery of antiviral agents through the use of redox targeting. Adv. Drug Delivery Rev. 14: 177-197.
54. Brewster, M. E., Estes, K. S. and Bodor, N. (1986) Improved delivery through biological membranes. XXIV. Synthesis, in vitro studies, and in vivo characterization of brain-specific and sustained progestin delivers systems. Pharm. Res. 3: 278-085.
55. Brewster, M. E., Estes, K. S. and Bodor, N. (1988) Improved delivery through biological membranes. XXXII. Synthesis and biological activity of brain-targeted delivery systems for various estradiol derivatives. J. Med. Chem. 31: 244-249.
56. Brownlees, J. and Williams, C. H. (1993) Peptidases, peptides, and the mammalian blood-brain barrier. J. Neurochem. 60: 793-803.
57. Buchwald, P. and Bodor, N. (1997) Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size based model. Proteins, in press.
58. Bundgaard, H. (ed.) (1985) Design of Prodrugs. Elsevier Science, Amsterdam.
59. Dewar, M. J. S., Zoebisch, E. G., Healy, E. F. and Stewart, J. J. P. (1985) AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107: 3902-3909.
60. Druzgala, P. and Bodor, N. (1991) Regioselective O-alkylation of cortienic acid and synthesis of a new class of glua corticoids containing a 17α-alkoxy, a 17α-(1′-alkoxyethyloxy), a 17α-alkoxymethyloxy, or a 17α-methylthiomethyloxy function. Steroids 56: 490-494.
61. Druzgala, P., Hochhaus, G. and Bodor, N. (1991) Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etahonate. J. Steroid Biochem. 38: 149-154.
62. El-Koussi, A. and Bodor, N. (1989) Formation of propanolol in the iris-ciliary body from its propranolol ketoxime precursor - a potential antiglaucoma drug. Int. J. Pharm. 53: 189-194.
63. Farag, H. H., Wu, W.-M., Barros, M. D. C., Somogyi, G., Prokai, L. and Bodor, N. (1997) Ocular-specific chemical delivery system of betaxolol for safe local treatment of glaucoma. Drug Des. Discov., in press.
64. Francis, R. J., East, P. B., McLaren, S. J. and Larman, J. (1976) Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatograpby with electron capture detection. Biomed. Mass Spectrom. 3: 281-285.
65. Friend, D. R. and Pangburn, S. (1987) Site-specific drug delivery. Med. Res. Rev. 7: 53-106.
66. Gaines, T. B. (1969) Acute toxicity of pesticides. Toxicol. Appl. Pharmacol. 14: 515-534.
67. Gardner, C. R. (1985) Potential and limitations of drug targeting: an overview. Biomaterials 6: 153-160.
68. Gogu, S. R., Aggarwal, S. K., Rangan, S. R. S. and Agrawal, K. C. (1989) A prodrug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochem. Biophys. Res. Commun. 160: 656-661.
69. Hamilton, T. C. and Chapman, V. (1978) Intrinsic sympathomimetic activity of β-adrenoceptor blocking drugs at cardiac and vascular β-adrenoceptors. Life Sci. 23: 813-820.
70. Hammer, R., Amin, K., Gunes, Z., Brouillette, G. and Bodor, N. (1988) Novel soft anticholinergic agents. Drug Des. Deliv. 2: 207-219.
71. Hammer, R. H., Wu, W.-M., Sastry, J. S. and Bodor, N. (1991) Short acting soft mydriatics. Curr. Eye Res. 10: 565-570.
72. Hansch, C., Leo, A. and Hoekman, D. (1995) Exploring QSAR. Hydrophobic, Electronic, and Steric Constants. American Chemical Society, Washington, DC.
73. IARC Monograph Series (1983) 30: 73-101.
74. Ihler, G. M., Glenn, R. H. and Schunke, F. W. (1973) Enzyme loading of erythrocytes. Proc. Natl. Acad. Sci. USA 70: 2663-2666.
75. Joseph, D. B. and Bidlak, J. M. (1996) The κ-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site. Eur. J. Pharmacol. 267: 1-6.
76. Kaminski, J. J., Bodor, N. and Higuchi, T. (1976a) N-Halo derivatives. III: Stabilization of nitrogen chlorine bond in N-chloroamino acid derivatives. J. Pharm. Sci. 65: 553-557.
77. Kaminski, J. J., Bodor, N. and Higuchi, T. (1976b) N-Halo derivatives. IV: Synthesis of low chlorine potential soft-N-chloramine systems. J. Pharm. Sci. 65: 1733-1737.
78. Kanematsu, K., Naito, R., Shimohigashi, Y., Ohno, M., Ogasawara, T., Kurono, M. and Yagi, K. (1990) Design and synthesis of an opiod receptor probe: mode of binding of S-activated (-)-6β-sulfhydryldihydromorphine with the SH group in the μ-opioid receptor. Chem. Pharm. Bull. 38: 1438-1440.
79. Kashyap, S. K., Nigam, S. K., Karnik, A. B., Gupta, R. C. and Chatterjee, S. K. (1979) Carcinogenicity of DDT (dichlorodiphenyltrichloroethane) in pure inbred Swiss mice. Int. J. Cancer 19: 725-729.
80. Korolkovas, A. (1988) Essentials of Medicinal Chemistry, 2nd edn. Wiley & Sons, New York.
81. Kourounakis, A., Bodor, N. and Smipkins, J. (1996) Synthesis and evaluation of a brain-targeted catechol derivative as a potential NGF-inducer. Int. J. Pharm. 141: 239-250.
82. Kourounakis, A., Bodor, N. and Simpkins, J. (1997) Synthesis and evaluation of a brain-targeted chemical delivery system for the neurotrophomodutator 4-methylcatechol. J. Pharm. Pharmacol. 49: 1-9.
83. Kumar, G. N., Hammer, R. H. and Bodor, N. (1993a) Soft drugs-12. Design, synthesis, stability and evaluation of soft anticholinergics. Drug Des. Discov. 10: 11-21.
84. Kumar, G. N., Hammer, R. H. and Bodor, N. (1993b) Soft drugs. 13. Design and evaluation of phenylsuccinic analogs of scopolamine as soft anticholinergics. Drug Des. Discov. 10: 1-9.
85. Kumar, G. N., Hammer, R. H. and Bodor, N. (1993c) Soft drugs. 16. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine. Bioorg. Med. Chem. 1: 327-332.
86. Kumar, G. N., Hammer, R. H., Wu, W.-M. and Bodor, N. (1993d) Soft drugs. 15. Mydriatic activity of phenylsuccinic analogs of methscopolamine and transcorneal penetration of short acting mydriatics. Curr. Eye Res. 12: 501-506.
87. Little, R., Bailey, D., Brewster, M. E., Estes, K., Clemmons, R., Saab, A. and Bodor, N. (1990) Improved delivery through biological membranes. XXXIII. Brain enhanced delivery of azidothymidine AZT. J. Biopharm. Sci. 1: 1-13.
88. Machin, P. J., Hurst, D. N. and Osbond, J. M. (1985) β-Adrenoceptor activity of the stereoisomers of the bufuralol alcohol and ketone metabolites. J. Med. Chem. 28: 1648-1651.
89. Meijer, D. K. F., Jansen, R. W. and Molema, G. (1992) Drug targeting systems for antiviral agents: options and limitations. Antiviral Res. 18: 215-258.
90. ONO Pharmaceutical Co. (1990) FPO Patent 386901, December 12, Japan.
91. Palomino, E., Kessel, D. and Horwitz, J. P. (1989) A dihydropyridine carrier system for sustained delivery of 1′,3′-dideoxynucleosides to the brain. J. Med. Chem. 32: 622-625.
92. 1 a site-activated ocular β-blocker, in dogs. Life Sci. 56: 1207-1216.
93. Pop, E., Wu, W.-M. and Bodor, N. (1989a) Chemical delivery systems for some penicillinase-resistant semisynthetic penicillins. J. Med. Chem. 32: 1789-1795.
94. Pop, E. Wu, W.-M., Shek, E. and Bodor, N. (1989b) Brain-specific chemical delivery systems for β-lactam antibiotics. Synthesis and properties of some dihydtopyridine and dihydroisoquinoline derivatives of benzylpenicillin. J. Med. Chem. 32: 1774-1781.
95. Poste, G., Kirsh, R. and Koestler, T. (1984) The challenge of liposome targeting in vivo. In: Liposome Technology, Vol. III, pp. 1-28, Gregoriadis, G. (ed.) CRC Press, Boca Raton.
96. Poznansky, M. S. and Juliano, M. S. (1984) Biological approaches to the controlled delivery of dings: a critical review. Pharmacol. Rev. 36: 277-287.
97. Prokai, L., Ouyang, X.-D., Wu, W.-M. and Bodor, N. (1994a) Chemical delivery system to transport a pyroglutamyl peptide to the central nervous system J. Am. Chem. Soc. 116: 2643-2644.
98. Prokai, L., Wu, W.-M., Somogyi, G. and Bodor, N. (1994b) Ocular delivery of the β-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analog. J. Med. Chem. 38: 2018-2020.
99. Prokai-Tatrai, K., Prokai, L. and Bodor, N. (1996) Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J. Med. Chem. 39: 4775-4782.
100. Raghavan, K., Shek, E. and Bodor, N. (1987) Improved delivery through biological membranes. XXX. Synthesis and biological aspects of a 1,4-dihydropyridine based chemical delivery system for brain-sustained delivery of hydroxy CCNU. Anticancer Drug Des. 2: 25-36.
101. Ranade, V. V. (1989) Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers. J. Clin. Pharmacol. 29: 685-094.
102. Rand, K., Bodor, N., El-Koussi, A., Raad, I., Miyake, A., Houck, H. and Gildersleeve, N. (1986) Potential treatment of herpes simplex virus encephalitis by brain-specific delivery of trifluorothymidine using a dihydropyridine ↔ pyridinium salt redox delivery system. J. Med. Virol. 20: 1-8.
103. Reddy, I. K. and Bodor, N. (1994) In vitro evaluation of a controlled-release site-specific diisovaleryl tert-butalone chemical delivery system for the eye. J. Pharm. Sci. 83: 450-453.
104. Saah, M., Wu, W.-M., Eberst, K., Marvanyos, E. and Bodor, N. (1996) Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue. J. Pharm. Sci. 85: 496-504.
105. Schubert, W. M. and Motoyama, Y. (1965) An example of SN1 cleavage of a sulfide. J. Am. Chem. Soc. 87: 5507-5508.
106. Shahrestanifar, M., Wang, W. W. and Howells, R. D. (1996) Studies on inhibition of μ and δ opioid receptor binding by dithiothreitol and N-ethylmaleimide. J. Biol. Chem. 271: 5505-5512.
107. Simay, A., Prokai, L. and Bodor, N. (1989) Oxidation of aryloxyβ-amino alcohols with activated dimethylsulfoxide. A novel C-N oxidation facilitated by neighboring group effect. Tetrahedron 45: 4091-4102.
108. Smith, J. R. and Simon, E. J. (1980) Selective protection of stereospecihc enkephalin and opiate binding against inactivation by N-ethylmaleimide: evidence for two classes of opiate receptors. Proc. Natl. Acad. Sci. USA 77: 281-284.
109. Tomlinson, E. (1987) Theory and practice of site-specific drug delivery. Adv. Drug Delivery Rev. 1: 87-164.
110. Tomlinson, E. and Davis, S. S. (eds.) (1987) Site-Specific Drug Delivery: Cell Biology, Medical, and Pharmaceutical Aspects. John Wiley and Sons, New York.
111. Torrence, P. T., Kinjo, J., Lesiak, K., Balzarini, J. and DeClerq, E. (1988) AIDS dementia: synthesis and properties of a derivative of 3′-azido-3′-deoxythimidine (AZT) that may become "locked" in the central nervous system. FEBS Lett. 234: 135-140.
112. Widder, K. J., Senyei, A. E. and Ramies, D. F. (1979) Magnetically responsive microspheres and other carriers for the biophysical targeting of amitumor agents. Adv. Pharmacol. Chemother. 16: 213-271.
113. Yang, H., Wu, W.-M. and Bodor, N. (1995) Soft drugs. XX. Design, synthesis and evaluation of ultra-short acting beta-blockers. Pharm. Res. 12: 329-336